Avrobio Inc (NASDAQ:AVRO) – Stock analysts at Svb Leerink decreased their FY2020 earnings per share (EPS) estimates for shares of Avrobio in a report released on Thursday, February 7th. Svb Leerink analyst M. Foroohar now anticipates that the company will post earnings of ($2.94) per share for the year, down from their previous estimate of ($2.84).
Other equities analysts have also issued reports about the stock. Zacks Investment Research raised shares of Avrobio from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a research report on Tuesday, January 15th. HC Wainwright reaffirmed a “buy” rating on shares of Avrobio in a research report on Tuesday, January 15th. ValuEngine lowered shares of Avrobio from a “buy” rating to a “hold” rating in a research report on Wednesday, October 24th. Finally, Leerink Swann lowered their price target on shares of Avrobio from $27.00 to $19.00 and set a “market perform” rating on the stock in a research report on Thursday, January 17th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $32.17.
NASDAQ:AVRO opened at $13.89 on Monday. Avrobio has a 52 week low of $11.85 and a 52 week high of $53.70.
Avrobio (NASDAQ:AVRO) last issued its quarterly earnings data on Tuesday, November 13th. The company reported ($0.49) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.91) by $0.42.
Hedge funds have recently added to or reduced their stakes in the business. Legal & General Group Plc bought a new position in Avrobio in the 3rd quarter valued at about $48,000. American International Group Inc. bought a new position in Avrobio in the 3rd quarter valued at about $210,000. Rhumbline Advisers bought a new position in Avrobio in the 3rd quarter valued at about $235,000. Man Group plc bought a new position in Avrobio in the 3rd quarter valued at about $329,000. Finally, New York State Common Retirement Fund bought a new position in Avrobio in the 4th quarter valued at about $113,000. 66.85% of the stock is currently owned by hedge funds and other institutional investors.
Avrobio Company Profile
AVROBIO, Inc, a clinical stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company's gene therapies employ hematopoietic stem cells that are extracted from the patient and modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease.
Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.